TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20053349
Drug: Oxandrolone 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 0.06 mg/kg/d
Study: 20053349
Drug: Oxandrolone 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 0.03 mg/kg/d or 0.06 mg/kg/d
Study: 18434455
Drug: Topical skin
Normalized name: Betadine 7.5% Topical Skin Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical skin coolant spray
Study: 8889425
Drug: Ibuprofen arginine
Normalized name: ibuprofen arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen arginine (400 mg)
Study: 8889425
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate (5 mg)
Study: 359108
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate (10 mg)
Study: 1797888
Drug: Allopurinol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (50 mg p.o. q.i.d.)
Study: 1797888
Drug: DMSO (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO (500 mg p.o. q.i.d.)
Study: 7316037
Drug: Closed suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Closed suction catheter with antibiotic irrigation
Study: 31794857
Drug: Self-management exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management exercise program (5 sessions) + spa therapy (18 days)
Study: 31794857
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (spa therapy only, 18 days)
Study: 25654519
Drug: Tailored exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored exercise program (6-month, twice-a-week)
Study: 24015719
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (1.4 g·kg body mass⁻¹)
Study: 24015719
Drug: Carbohydrate (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (1.1 g·kg body mass⁻¹)
Study: 24015719
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (1.4 g·kg body mass⁻¹)
Study: 17381533
Drug: dCa 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: dCa 1.5 mmol/L for three months, then dCa 1.25 mmol/L for three months (ABD-treated group)
Study: 17381533
Drug: dCa 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: dCa 1.5 mmol/L for three months, then dCa 1.25 mmol/L for three months (sHPT-treated group)
Study: 17381533
Drug: dCa 1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: dCa 1.75 mmol/L (ABD-control group)
Study: 17381533
Drug: dCa 1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: dCa 1.75 mmol/L (sHPT-control group)
Study: 15446659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of effortful and automatic strategies
Study: 23116237
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone therapy (o-HT)
Study: 23116237
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone therapy (t-HT)
Study: 21606296
Drug: 80-kVp protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-kVp protocol with low-dose contrast material (444 mg I/kg body weight) delivered over 15 seconds
Study: 21606296
Drug: 80-kVp protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-kVp protocol with low-dose contrast material
Study: 21606296
Drug: 120-kVp protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120-kVp protocol with standard-dose contrast material (600 mg I/kg) delivered over 30 seconds
Study: 21606296
Drug: 120-kVp protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120-kVp protocol with standard-dose contrast material
Study: 19339135
Drug: High counseling
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High counseling combined with bupropion or nicotine patch
Study: 19339135
Drug: Low counseling
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low counseling combined with bupropion or nicotine patch
Study: 15389222
Drug: Abciximab and
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab and half-dose reteplase followed by conventional medical therapy (with referral for emergency rescue PTCA allowed in selected cases)
Study: 15389222
Drug: Abciximab and
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab and half-dose reteplase followed by emergency angioplasty
Study: 15389222
Drug: Abciximab and
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab and half-dose reteplase
Study: 11590972
Drug: Typical antipsychotic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotic treatment
Study: 9850430
Drug: Phenylpropanolamine 50
Normalized name: phenylpropanolamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine 50 mg administered at 22.00 h
Study: 9850430
Drug: Phenylpropanolamine 50
Normalized name: phenylpropanolamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine 50 mg administered at 10.00 h
Study: 706
Drug: L-Dopa (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dopa (900 mg + 225 mg benserazid daily)
Study: 706
Drug: L-Dopa (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dopa (600 mg + 150 mg benserazid)
Study: 706
Drug: L-Dopa (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dopa (300 mg + 75 mg benserazid)
Study: 30262209
Drug: EPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPAP therapy
Study: 20817013
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg HA antigen dose
Study: 20817013
Drug: Two 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 15 μg HA doses
Study: 20817013
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg HA antigen dose
Study: 20817013
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of 30 μg HA antigen
Study: 20817013
Drug: Vaccine overall
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine overall
Study: 18399337
Drug: Misoprostol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (50 microg intravaginally every 6 hours, maximum of 4 doses)
Study: 10457872
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg followed by 800 micrograms of misoprostol (phase 1)
Study: 10457872
Drug: Methotrexate 50
Normalized name: methotrexate 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 50 mg/m2 followed by 800 micrograms of misoprostol (phase 1)
Study: 10457872
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg twice daily for 4 days followed by 800 micrograms of misoprostol (phase 2)
Study: 2467711
Drug: Iloprost intravenous
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost intravenous infusions starting at 0.5 ng/kg/min and increased by 0.5 ng/kg/min every 15 minutes to a maximum of 2.0 ng/kg/min for eight hours on three consecutive days with a further single infusion at week 8.
Study: 2467711
Drug: Nifedipine starting
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine starting at 30 mg daily and increased to 60 mg daily after four weeks for another 12 weeks.
Study: 135163
Drug: Dimenhydrinate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate (2 mg/kg)
Study: 135163
Drug: Sulpirid (2.86
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpirid (2.86 mg/kg)
Study: 25197025
Drug: ISIS 325568
Normalized name: ISIS 325568
DrugBank: ISIS 325568 (DB06099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 325568 (400 mg/week)
Study: 23635996
Drug: MgSO4 30
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MgSO4 30 mg kg(‐1) intravenously for 10 min, then continuous infusion at 1 g h(‐1)
Study: 21957896
Drug: Quinapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril treatment for 3 months
Study: 19123333
Drug: Combined massage-smouldering-washing
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined massage-smouldering-washing therapy (MSW)
Study: 19123333
Drug: Mini-invasive surgery
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-invasive surgery by arthroscopic mopping with sodium hyaluronate injection
Study: 16297965
Drug: Patch tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch tests for sensitivity to cadmium
Study: 7693029
Drug: 5 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms/kg rG‐CSF after induction therapy
Study: 7693029
Drug: 10 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms/kg rG‐CSF after induction therapy
Study: 7693029
Drug: 2 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 micrograms/kg rG‐CSF after consolidation therapy
Study: 7693029
Drug: 5 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms/kg rG‐CSF after consolidation therapy
Study: 7693029
Drug: 10 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms/kg rG‐CSF after consolidation therapy
Study: 7693029
Drug: No rG‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rG‐CSF after consolidation therapy
Study: 27144545
Drug: Wild-type KRAS
Normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild-type KRAS patients treated with anti-EGFR agent
Study: 18795588
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg (for patients initially on RSV 10 mg who were uncontrolled)
Study: 18795588
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from Atorvastatin 10 mg to Rosuvastatin 10 mg (for patients initially on ATV 10 mg who were uncontrolled)
Study: 8599316
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g supplemental Ca/d as calcium carbonate (in lactating and nonlactating women)
Study: 30485409
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of relaxation and physical activity
Study: 27193480
Drug: Two implant-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two implant-supported overdentures
Study: 27193480
Drug: Four implant-supported
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four implant-supported overdentures
Study: 20653227
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of background visual motion and relative movement of sound while sitting at a desk
Study: 8417512
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Hydralazine + Nitroglycerin)
Study: 2941277
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 100 mg
Study: 2941277
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 750 mg
Study: 2941277
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 250 mg (after breakfast)
Study: 2941277
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 200 mg (20 min infusion)
Study: 2941277
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (various doses)
Study: 2941277
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin (various doses)
Study: 2941277
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 250 mg
Study: 29901903
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose MgSO4 (10 gm)
Study: 29901903
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose MgSO4 (5 gm)
Study: 20145260
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) moxifloxacin
Study: 31003911
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus cobimetinib (840 mg intravenously every 2 weeks + 60 mg orally once daily for days 1–21 of a 28-day cycle)
Study: 31003911
Drug: Atezolizumab monotherapy
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab monotherapy (1200 mg intravenously every 3 weeks)
Study: 31003911
Drug: Regorafenib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (160 mg orally once daily for days 1–21 of a 28-day cycle)
Study: 23859672
Drug: 2 g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of cefazolin
Study: 23859672
Drug: 4 g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of cefazolin
Study: 15088127
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous interleukin 2 (IL-2) and interferon alpha (IFN-alpha) alone (n = 23)
Study: 15088127
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous interleukin 2 (IL-2) and interferon alpha (IFN-alpha) in combination with histamine dihydrochloride (n = 26)
Study: 15088127
Drug: Cytokine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine therapy (IL-2 and IFN-alpha)
Study: 11418230
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment (for those with high PRL response)
Study: 11418230
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment (for those with low PRL response)
Study: 9876958
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg xanomeline tartrate three times daily (t.i.d.)
Study: 7976162
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide 0.6 mg kg‐1 during balanced anesthesia (nitrous oxide and fentanyl)
Study: 7976162
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide 0.6 mg kg‐1 during halothane anesthesia
Study: 7976162
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide 0.9 mg kg‐1 during balanced anesthesia (nitrous oxide and fentanyl)
Study: 7976162
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide 0.9 mg kg‐1 during halothane anesthesia
Study: 7976162
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide 0.9 mg kg‐1 during anesthesia with nitrous oxide, oxygen, and isoflurane
Study: 2514694
Drug: Glycolande N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycolande N (modified glibenclamide formulation)
Study: 2514694
Drug: Marketed standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed standard preparation (glibenclamide)
Study: 1104076
Drug: Tetrabid-Organon (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabid-Organon (sustained-release tetracycline hydrochloride)
Study: 27876790
Drug: MR-antagonist spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MR-antagonist spironolactone
Study: 18714620
Drug: Traditional continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional continuous intravenous infusion
Study: 16441475
Drug: Polyethylene glycol-electrolyte
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-electrolyte solution (PEG-ELS)
Study: 12940870
Drug: Isoflavones from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones from red clover (approximately 50 mg/day for 4 weeks)
Study: 10741114
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of Iopamiron 300 mgI/ml (group 1)
Study: 10741114
Drug: 2 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml/kg of Iopamiron 300 mgI/ml (group 2)
Study: 1396619
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg daily
Study: 1396619
Drug: Timolol 10
Normalized name: timolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 10 mg daily
Study: 2865710
Drug: Levobunolol (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobunolol (0.5% and 1%) twice daily
Study: 29747594
Drug: Clinic referral
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic referral / ongoing treatment (Treated Group)
Study: 29747594
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment (No Treatment Group)
Study: 16235460
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of hyperbaric bupivacaine combined with 2 mg of midazolam intrathecally (M+M)
Study: 16235460
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of hyperbaric bupivacaine (M)
Study: 10973391
Drug: Optimal values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal values (cardiac index >4.5 L/min/m2, ratio of transcutaneous oxygen tension to fractional inspired oxygen >200, oxygen delivery index >600 mL/min/m2, and oxygen consumption index >170 mL/min/m2)
Study: 8993081
Drug: Fluoxetine; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine; specific dosage and duration not mentioned
Study: 8993081
Drug: Placebo; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; specific dosage and duration not mentioned
Study: 1620908
Drug: Sham pulsations
Normalized name: ABG Pulsator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham pulsations (placebo treatment)
Study: 27892594
Drug: Chloroprocaine 10
Normalized name: chloroprocaine 10 mg/mL intrathecal solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine 10 mg/ml (10 mg)
Study: 27892594
Drug: Chloroprocaine 10
Normalized name: chloroprocaine 10 mg/mL intrathecal solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine 10 mg/ml (20 mg)
Study: 27892594
Drug: Chloroprocaine 10
Normalized name: chloroprocaine 10 mg/mL intrathecal solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine 10 mg/ml (30 mg)
Study: 26614144
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg kg(‐1) induction, 6‐10 mg kg(‐1)h(‐1) maintenance
Study: 26614144
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg kg(‐1) induction, 0.5 mg kg(‐1) maintenance
Study: 22185846
Drug: Hibiscus sabadariffa
Normalized name: Hibiscus sabdariffa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscus sabadariffa extract (SHE) standardized 10 mg of anthocyanins
Study: 22185846
Drug: Hibiscus sabadariffa
Normalized name: Hibiscus sabdariffa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscus sabadariffa extract (SHE) standardized 20 mg of anthocyanins for 12 weeks
Study: 11510804
Drug: Keliximab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keliximab 0.5 mg/kg
Study: 11510804
Drug: Keliximab 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keliximab 1.5 mg/kg
Study: 11510804
Drug: Keliximab 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keliximab 3.0 mg/kg
Study: 11510804
Drug: Keliximab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keliximab (all doses combined)
Study: 9764780
Drug: pVL nadir
Normalized name: NAIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: pVL nadir < or = 20 copies/ml
Study: 9764780
Drug: pVL nadir
Normalized name: NAIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: pVL nadir between 20 and 400 copies/ml
Study: 9764780
Drug: pVL nadir
Normalized name: NAIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: pVL nadir > 400 copies/ml
Study: 3296353
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) treatment for 90 days followed by conversion to azathioprine and prednisolone
Study: 3296353
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (AP) with azathioprine and prednisolone throughout
Study: 17935920
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 1 ml methylprednisolone (40 mg/ml), 0.5 ml Lidocaine (5mg/ml), and 0.15 ml gadolinium (Omniscan 0.5 mmol/ml) into the wrist joint.